Effect of enteral administration of insulin on intestinal development and feeding tolerance in preterm infants: a pilot study

R J Shulman

Objective: To determine in a pilot study whether enteral administration of insulin to preterm infants (26–29 weeks of gestational age) would enhance gastrointestinal development and reduce feed intolerance without adverse effects.

Design: Eight preterm infants were given 4 U/kg/day insulin enterally from 4 to 28 days of age. Lactase activity was measured at 28 days of age, while measures of feed intolerance were made throughout the hospital stay. The results were compared with those of a matched historical cohort of 80 preterm infants.

Setting: Tertiary care, university affiliated hospital.

Main outcome measures: Lactase activity and feed intolerance.

Results: No adverse effects, such as hypoglycaemia, were observed after administration of insulin. The infants who received insulin had higher lactase activity and less feed intolerance than the controls (30% shorter time to full enteral feeds; fewer gastric residuals per infant).

Conclusions: These preliminary data suggest that enteral insulin administration may be of benefit in reducing feed intolerance in preterm infants. A randomised, blinded trial is warranted.

Feeding preterm infants is a formidable task because of their gastrointestinal (GI) immaturity. Previous studies have shown that a number of their GI functions are underdeveloped compared with those of the term infant. GI functions such as lactase activity and motor function undergo their most significant development during the last trimester. Animal studies have shown that maternal milk contains a number of factors that can enhance development of the immature GI tract. Of these, insulin is present in maternal milk at levels three to fourfold higher than in maternal blood.

Insulin has been shown both in vitro and in vivo to accelerate a number of GI functions. More recently, enteral administration of insulin to newborn pigs and rats has been shown to enhance development of intestinal activity and growth.

The present pilot study was carried out to determine whether enteral administration of insulin to preterm infants would enhance their gastrointestinal development and reduce feed intolerance. A large, randomised, placebo controlled trial would be required to irrefutably resolve this question. Before embarking on such an investigation, however, preliminary evidence must be obtained to show that insulin is efficacious, optimally in the form of a pilot trial such as the one conducted and described here, delineating the manifestations and magnitude of such an effect.

MATERIALS AND METHODS

Study population

Two groups of infants were compared. Eight insulin treated infants were enrolled during 1997. They were selected sequentially from the Texas Children's Hospital nursery by criteria used in a prospective feeding trial in 1992–1997. The infants recruited met the following criteria: 26–30 weeks gestation, determined by a combination of maternal dates and early antenatal ultrasound; gestational age agreement between the two methods of two weeks or less; appropriate size for gestational age; postnatal age ≤ 96 hours; absence of major congenital malformations; and fraction of inspired oxygen < 0.60 at 72 hours.

Parenteral nutrition was used until the infants achieved complete enteral feeds, and was adjusted to provide a total intake (enteral and parenteral) of 120 kcal/kg/day. The infants received either human milk or Enfamil Premature Formula (Mead-Johnson Nutritional Division, Evansville, Indiana, USA) if the mothers had inadequate milk production. Management of the infants was at the discretion of the attending neonatologists without input from the investigator.
Standard care of infants in the nursery did not change appreciably over the observation period. In addition, the large number of neonatologists at the institution helps to ensure that no one doctor has an inordinate influence on patient care.

**Effect of insulin on blood glucose**

To determine the effects of enteral insulin on serum glucose concentration, they were measured at 0, 30, and 90 minutes after the first, second, and fifth doses of insulin.

**Measurement of lactase activity**

Intestinal lactase activity in both groups of infants was determined at 28 days of age using the method of Weaver et al. This method has been validated by comparison with direct measurements of lactase activity in biopsy specimens of small intestine in the same patients. In addition, changes in the ratio correlate with clinical observations on disaccharidase intolerance were made by the attending doctor according to a published algorithm.

**Measures of feeding intolerance**

Measures of feed intolerance were monitored throughout the hospital stay for both groups. For the insulin treated infants and control infants (n = 80), the number of residuals > 2 ml/kg and borderline significant for residuals that were > 50% of the volume of the previous feed were recorded. There were no differences between groups with respect to the age at discharge (75 (33) days insulin group versus 81 (33) days control group). No untoward effects of the insulin treatment were observed.

**DISCUSSION**

A large part of the morbidity associated with preterm birth is related to feed intolerance. Given that term infants rarely experience feeding difficulties, it is accepted that feed intolerance in the preterm infant is related to GI immaturity. Although various feeding trials and treatments have attempted to ameliorate feed intolerance, they have met with limited success.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical characteristics of preterm infants given insulin or not (controls)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Insulin group (n=8)</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>27.8 (2.5)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>973 (310)</td>
</tr>
<tr>
<td>Age feeds begun (days)</td>
<td>9.9 (4.3)</td>
</tr>
<tr>
<td>Percentage of feeds with human milk</td>
<td>30 (32)</td>
</tr>
<tr>
<td>Age at lactase measurement (days)</td>
<td>29 (3)</td>
</tr>
<tr>
<td>Antenatal glucocorticoids (n)</td>
<td>4 (50%)</td>
</tr>
</tbody>
</table>

Values are mean (SD).

Data analysis

Differences between groups were compared using Student’s t test. Mann-Whitney analysis was used for data not normally distributed. The data are expressed as mean (SD) or median and range as appropriate.

**RESULTS**

The clinical characteristics of the insulin treated and control infants were well matched (table 1). There was no evidence of hypoglycaemia after the first, second, or fifth dose of insulin (baseline: 8.9 (3.2) mmol/l; 30 min: 9.7 (3.1) mmol/l; 90 min: 9.6 (2.9) mmol/l; mean (SD) for first dose; other data not shown). No untoward effects of the insulin treatment were observed.

At 28 days of age, median lactase activity was higher in the insulin group than in the control group (table 2; fig 1). Lactase measurements were available for six of the eight insulin treated infants and 43 of the controls. The insulin treated infants achieved full enteral feeds earlier and at a younger age than did the controls (table 2).

The insulin treated infants had fewer gastric residuals than the control infants (table 2). This was significant for the number of residuals > 2 ml/kg and borderline significant for residuals that were > 50% of the volume of the previous feed (table 2). There were no differences between groups with respect to the age at discharge (75 (30) days insulin v 81 (33) days control).

**Figure 1** Scattergram of lactase activity at 28 days of age in the insulin and control groups (n = 6 and 43 respectively; samples could not be obtained from all infants for various reasons, such as the parents and/or attending doctor requesting that the test was not performed or the infants were unstable). The horizontal lines represent the median values. Lactase activity was determined using the urine/milk lactulose/lactose ratio.

**Table 2** Lactase activity and measures of feeding intolerance in preterm infants given insulin or not (controls)

<table>
<thead>
<tr>
<th></th>
<th>Insulin group (n=8)</th>
<th>Control group (n=80)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactase activity</td>
<td>13.3 (6.7–65.4)</td>
<td>6.5 (0.43–54.76)</td>
<td>0.023</td>
</tr>
<tr>
<td>Age at full enteral feeds (days)</td>
<td>21 (6)</td>
<td>31 (13)</td>
<td>0.004</td>
</tr>
<tr>
<td>Days to full enteral feeding</td>
<td>11 (6)</td>
<td>20 (16)</td>
<td>0.007</td>
</tr>
<tr>
<td>Mean number per infant</td>
<td>11 (6)</td>
<td>31 (13)</td>
<td>0.004</td>
</tr>
<tr>
<td>Gastric residuals &gt;2 ml/kg</td>
<td>22 (17)</td>
<td>54 (44)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Values are median (range) or mean (SD).
In vitro and in vivo work in animals documents the ability of insulin to enhance GI development and function.\textsuperscript{1,2} A growing body of literature from studies in various animal species supports the idea that administration of enteral insulin also accelerates GI development.\textsuperscript{3–11} Insulin is attractive as an agent to enhance GI development in the preterm infant. It is normally present in human milk at high concentrations relative to maternal blood.\textsuperscript{12} It is not absorbed systemically to any significant degree as measured by changes in blood sugar in this study and in a previous investigation.\textsuperscript{13} It is inexpensive and readily available.

The results of this study suggest that enteral administration of insulin to preterm infants enhances GI function, as measured by increased lactase activity (table 2, fig 1). Previous studies have documented the importance of lactase activity and lactose digestibility in reducing feed intolerance in preterm infants.\textsuperscript{14–16} It must be explored in future trials.

A limitation of this preliminary study is the retrospective nature of the control infants. However, management of the insulin treated and control infants was similar as it was controlled by nursery protocol.\textsuperscript{17} Further, the investigator had no input into the management of any infants as this was in the hands of the various attending neonatologists. Recent studies have documented the value of similar case-controlled investigations.\textsuperscript{18–20}

The goal of this study was to ascertain whether there was evidence that insulin is efficacious in enhancing GI development and reducing feed intolerance in preterm infants. Given that these pilot data support this hypothesis, I suggest that a formal investigation of this hypothesis, funded by an NIH grant, be continued. This study was supported by the Daffy's Foundation and the USDA/ARS.

ACKNOWLEDGEMENTS

This study was supported by the Daffy's Foundation and the USDA/ARS under Cooperative Agreement No 58–6250–1–003. This work is a publication of the USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX. The contents of this publication do not necessarily reflect the views or policies of the USDA, nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government.

REFERENCES

Effect of enteral administration of insulin on intestinal development and feeding tolerance in preterm infants: a pilot study
R J Shulman

Arch Dis Child Fetal Neonatal Ed 2002 86: F131-F133
doi: 10.1136/fn.86.2.F131

Updated information and services can be found at:
http://fn.bmj.com/content/86/2/F131

These include:

References
This article cites 23 articles, 3 of which you can access for free at:
http://fn.bmj.com/content/86/2/F131#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Child health (1515)
Infant health (857)
Neonatal health (928)
Diabetes (128)
Metabolic disorders (291)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/